NAMS
NewAmsterdam Pharma Company N.V. · Healthcare
34.12
3.43%(+1.13)
Prev. Close40.50
18.70%(+6.38)
Pre-marketLast Updated: — ET
52W L: $14.2852W H: $42.00
$34.40
CHG+4.67 (+15.71%)
H$34.99
L$28.02
VOL13M
NAMS (1h)
NewAmsterdam Pharma Company N.V. · Healthcare
NewAmsterdam Pharma (NASDAQ: NAMS - Get Free Report) and Shineco (NASDAQ: SISI - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership. Institutional and Insider Ownership 89.9% of NewAmsterdam Pharma shares
Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 729,484 shares of the company's stock after purchasing an additional 67,538 shares during the period. Aberdeen Group plc owned
NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana.
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 101,409 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the sale, the insider owned 69,302 shares in the company,
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS - Get Free Report) insider Johannes Jacob Piete Kastelein sold 104,467 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the sale, the insider owned 69,302 shares of the company's stock,
LANGE LOUIS G
director
44,173 SH @ $30.41
2026-03-11
LANGE LOUIS G
director
446 SH @ $31.23
2026-03-11
LANGE LOUIS G
director
44,619 SH @ $11.50
2026-03-09
LANGE LOUIS G
director
44,619 SH @ $11.50
2026-03-09
LANGE LOUIS G
director
28,186 SH @ $29.41
2026-03-06
Kastelein Johannes Jacob Pieter
director, officer: Chief Scientific Officer
104,467 SH @ $0.00
2026-03-05
Kastelein Johannes Jacob Pieter
director, officer: Chief Scientific Officer
94,124 SH @ $0.00
2026-03-06
Kastelein Johannes Jacob Pieter
director, officer: Chief Scientific Officer
101,409 SH @ $0.00
2026-03-09